IMPEL NEUROPHARMA INC (IMPL): Price and Financial Metrics


IMPEL NEUROPHARMA INC (IMPL): $3.44

-0.04 (-1.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMPL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMPL POWR Grades

  • Growth is the dimension where IMPL ranks best; there it ranks ahead of 62.97% of US stocks.
  • IMPL's strongest trending metric is Value; it's been moving up over the last 178 days.
  • IMPL's current lowest rank is in the Quality metric (where it is better than 9.91% of US stocks).

IMPL Stock Summary

  • IMPL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.46 -- higher than only 4.21% of US-listed equities with positive expected earnings growth.
  • IMPEL PHARMACEUTICALS INC's stock had its IPO on April 23, 2021, making it an older stock than merely 5.72% of US equities in our set.
  • As for revenue growth, note that IMPL's revenue has grown 1,130.69% over the past 12 months; that beats the revenue growth of 99.05% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to IMPEL PHARMACEUTICALS INC, a group of peers worth examining would be XERS, TELA, BIOL, PWFL, and MYSZ.
  • IMPL's SEC filings can be seen here. And to visit IMPEL PHARMACEUTICALS INC's official web site, go to www.Impelnp.com.

IMPL Valuation Summary

  • IMPL's price/sales ratio is 10.2; this is 100% higher than that of the median Healthcare stock.
  • Over the past 21 months, IMPL's EV/EBIT ratio has gone up 5.8.

Below are key valuation metrics over time for IMPL.

Stock Date P/S P/B P/E EV/EBIT
IMPL 2023-01-20 10.2 -3.8 -0.8 -0.6
IMPL 2023-01-19 10.3 -3.8 -0.8 -0.6
IMPL 2023-01-18 9.7 -3.6 -0.7 -0.5
IMPL 2023-01-17 10.0 -3.7 -0.8 -0.5
IMPL 2023-01-13 10.1 -3.7 -0.8 -0.6
IMPL 2023-01-12 10.3 -3.8 -0.8 -0.6

IMPL Price Target

For more insight on analysts targets of IMPL, see our IMPL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.00 Average Broker Recommendation 1.17 (Strong Buy)

IMPL Stock Price Chart Interactive Chart >

Price chart for IMPL

IMPL Price/Volume Stats

Current price $3.44 52-week high $10.75
Prev. close $3.48 52-week low $2.52
Day low $3.44 Volume 2,855
Day high $3.56 Avg. volume 25,271
50-day MA $3.30 Dividend yield N/A
200-day MA $5.97 Market Cap 81.66M

IMPEL NEUROPHARMA INC (IMPL) Company Bio


Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.


IMPL Latest News Stream


Event/Time News Detail
Loading, please wait...

IMPL Latest Social Stream


Loading social stream, please wait...

View Full IMPL Social Stream

Latest IMPL News From Around the Web

Below are the latest news stories about IMPEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IMPL as an investment opportunity.

JonesTrading Sticks to Their Buy Rating for Impel NeuroPharma Inc (IMPL)

JonesTrading analyst Sean Kim PhD reiterated a Buy rating on Impel NeuroPharma Inc (IMPL - Research Report) today and set a price target of $22.00. The company's shares opened today at $3.36.Kim PhD covers the Healthcare sector, focusing on stocks such as Concert Pharma, Satsuma Pharmaceuticals, and Ocuphire Pharma. According to TipRanks, Kim PhD has an average return of -14.9% and a 38.10% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Impel NeuroPharma Inc with a $13.50 average price target.

Christine Brown on TipRanks | November 15, 2022

Investors in Impel Pharmaceuticals (NASDAQ:IMPL) have unfortunately lost 67% over the last year

The nature of investing is that you win some, and you lose some. And there's no doubt that Impel Pharmaceuticals Inc...

Yahoo | November 14, 2022

Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year After Launch Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, toda

Yahoo | November 14, 2022

Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on Tuesday, November 15, 2022 at 1:00 p.m. ET in New York, NY. A live webcast of the event will be

Yahoo | November 8, 2022

Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, November 14, 2022, at 8:30 a.m. ET to report its third quarter 2022 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.ve

Yahoo | November 7, 2022

Read More 'IMPL' Stories Here

IMPL Price Returns

1-mo 6.50%
3-mo -13.57%
6-mo -57.37%
1-year -65.08%
3-year N/A
5-year N/A
YTD -8.27%
2022 -56.55%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7125 seconds.